The sponsor has announced the discontinuation of this study due to a higher-than-expected rate of adverse events. If you would like to discuss this further, please contact your CF care team. The aim of this Phase 2b study is to further assess the safety and effectiveness of a new nebulised phage (BX004) medicine for the treatment of chronic Psuedomonas aeruginosa (PsA) lung infection in people with CF. The end goal is to see if after BX004 treatment the amount of PsA in sputum samples has decreased. BX004 contains five natural bacteriophages. A bacteriophage is a type of virus that only...
Content warning: this update includes mentions of mental health and suicidal thoughts.
This week, Vertex have announced that the labelling of CF modulator treatments in the US has been updated to include symptoms of anxiety, depression, suicidal thoughts, and sleep deprivation.
In February, our Patron, His Majesty King Charles III, and The Queen hosted a reception at Windsor Castle, recognising the work of paid and unpaid carers. We spoke to Jemma, Judith and Jess, who all attended the event.
